Expert Interviews

STEP 1 and STEP 3 Results with Thomas Wadden, PhD

March 02, 2021

Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.